Pyrazine-containing compound
Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling.
1. A compound having the chemical name N-(2,6-difluorobenzyl)-5-(1-ethyl-3-(thiazol-2-yl)-1H-pyrazol-5-yl)pyrimidin-2-amine or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient thereof.
3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is formulated as an oral composition.
4. A method for treating pancreatitis in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound having the chemical name N-(5-(7-chloro-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-2-yl)-2,6-difluorobenzamide, or N-(2,6-difluorobenzyl)-5-(1-ethyl-3-(thiazol-2-yl)-1H-pyrazol-5-yl)pyrimidin-2-amine, or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , wherein the pancreatitis is chronic pancreatitis.
6. The method of claim 4 , wherein the pancreatitis is associated with an inflammatory response in a subject.
7. The method of claim 6 , wherein the inflammatory response is a chronic inflammatory response.
8. The method of claim 7 , wherein the inflammatory response is a chronic inflammatory disease.
9. The method of claim 8 , wherein the chronic inflammatory disease is T helper 17 cell (Th17) induced.
10. The method of claim 9 , further comprising inhibiting Th17 differentiation.
11. The method of claim 6 , wherein the inflammatory response is associated with a group of inflammatory mediators consisting of TNF-α and IL-1.
12. The method of claim 4 , wherein the administering is oral.
13. The method of claim 4 , wherein the compound is or N-(2,6-difluorobenzyl)-5-(1-ethyl-3-(thiazol-2-yl)-1H-pyrazol-5-yl)pyrimidin-2-amine or a pharmaceutically acceptable salt thereof.
14. The method of claim 4 , wherein the compound is N-(5-(7-chloro-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-2-yl)-2,6-difluorobenzamide or a pharmaceutically acceptable salt thereof.